Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price has languished in 2024 while the market has flourished.

During the period, the biotechnology giant's shares have lost approximately 3% of their value.

This compares unfavourably to the performance of the ASX 200 index, which is up over 10% year to date. And that excludes the dividends paid over the period, which add somewhere in the region of 4%.

Perhaps the most disappointing part of this is that over the past couple of decades, the CSL share price has built a reputation of being a market-beater.

But we just simply have not seen this since the pandemic for a number of reasons. Since late 2019, CSL's shares have gone sideways.

But those lost years could be a thing of the past in the near future with analysts tipping CSL to find its way again.

A group of men in the office celebrate after winning big.

Image source: Getty Images

CSL share price tipped to rise strongly

According to a recent note out of Bell Potter, its analysts believe that the company is about to embark on a journey of strong and consistent growth.

In light of this, its analysts feel that the CSL share price is now being undervalued by the market.

Commenting on why it thinks now could be a good time to invest in the company, the broker said:

CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

In our view the stock looks undervalued on a PE ratio 18%/8% below 5yr/10yr historical averages and is set for double-digit earnings growth driven by the core Behring division.

The note reveals that Bell Potter has a buy rating and $345.00 price target on CSL's shares. Based on its current share price of $280.74, this implies potential upside of almost 17% for investors over the next 12 months.

To put this into context, a $5,000 investment in the company would turn into approximately $5,800 by this time next year if Bell Potter is on the money with its recommendation.

Overall, this could make CSL a great option for investors that are wanting to add some high-quality stocks to their portfolio for 2025.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

ASX 200 healthcare shares down 33% in a year as heavyweights hit multi-year lows

Eight of the 10 largest healthcare shares are trading at or close to multi-year or 52-week lows.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Healthcare Shares

Up 2,075% in a year, why is the 4DMedical share price rocketing again on Friday?

Investors just sent 4DMedical shares surging another 20% on Friday. But why?

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Healthcare Shares

Buy, hold, sell: What is Ord Minnett saying about this popular ASX 200 stock?

Here's what the broker is saying about this stock.

Read more »

A man in a shirt and tie looks to the horizon holding his hand above his eyes as if to shield the sun so he can see better.
Healthcare Shares

Why is everyone talking about 4DX shares this week?

It's all eyes on the healthcare stock this week.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

This stock has experienced a dramatic price increase.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The ASX healthcare stocks with the biggest upside according to brokers

These two healthcare stocks could be value buys.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Here's one reason why experts think the CSL share price can rise 65%!

There’s more than one reason why experts are excited by the potential of CSL.

Read more »